Evidence map›Paper›PMID 38575156›Full record

ArticleBMJ open diabetes research & care2024

Role of kidney function on Nrf2 mRNA levels in type 2 diabetes.

Belinda Spoto, Cristina Politi, Maurizio Postorino, Rosa Maria Parlongo, Alessandra Testa, Giovanni Luigi Tripepi, Francesca Mallamaci, Carmine Zoccali

Open access · goldAbstract read
In one paragraph

Article in BMJ open diabetes research & care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. NRF2 Dysregulation and Therapeutic Insights Across Chronic Kidney Diseases.International journal of molecular sciences · 2025
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Belinda SpotoInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy belinda.spoto@tin.it.ORCID 0000-0001-9679-3890
Cristina PolitiInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy.
Maurizio PostorinoNephrology, Dialysis and Transplantation Unit (GOM-BMM), Reggio Calabria, Italy.
Rosa Maria ParlongoInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy.
Alessandra TestaInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy.
Giovanni Luigi TripepiInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy.
Francesca MallamaciInstitute of Clinical Physiology Reggio Calabria Branch National Research Council, Reggio Calabria, Italy.
Carmine ZoccaliRenal Research Institute New York, New York, New York, USA.
Istituto di Fisiologia Clinica · ITBiogem · ITUniversity of Reggio Calabria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDiabetic kidney disease (DKD) is a major complication in patients with diabetes and the main contributor to the chronic kidney disease (CKD) global burden. Oxidative stress is a crucial factor in DKD pathogenesis but the role of the antioxidant nuclear factor erythroid 2-related factor 2 (Nrf2) and its molecular regulators has been poorly investigated in man. RESEARCH DESIGN AND

methodsIn this case-control study, we analyzed the roles of Nrf2, a transcription factor shielding cells from oxidative stress, its repressor Kelch-like ECH-associated protein 1 (Keap1) and six microRNAs (miRNAs) that potentially suppress Nrf2. We categorized 99 participants into 3 groups: 33 non-dialysis patients with type 2 diabetes with DKD, 33 patients with type 2 diabetes without DKD and 33 control subjects and quantified the gene expression (messenger RNA (mRNA)) levels of Nrf2, Keap1 and 6 miRNAs. Moreover, we studied the correlation between gene expression levels and clinical indicators of kidney health.

resultsIn patients with diabetes with DKD, Nrf2 mRNA levels were significantly lower than in patients without DKD (p=0.01) and controls (p=0.02), whereas no difference in Nrf2 expression levels existed between patients without DKD and controls. Conversely, in patients with and without DKD, Keap1 expression levels were significantly higher than in controls. Of the six miRNAs studied, miRNA 30e-5p showed differential expression, being markedly reduced in patients with DKD (p=0.007). Nrf2 mRNA levels directly correlated with estimated glomerular filtration rate (eGFR) in patients with DKD (r=0.34, p=0.05) and in a formal mediation analysis the eGFR emerged as the first factor in rank for explaining the difference in Nrf2 mRNA levels between patients with and without DKD.

conclusionsThe observed dysregulation in the Nrf2-Keap1 axis and the unique expression pattern of miRNA30e-5p in DKD underscore the need for more focused research in this domain that can help identify novel intervention strategies for DKD in patients with type 2 diabetes.

Indexed as

Diabetes Mellitus, Type 2MicroRNAsCase-Control StudiesHumansKelch-Like ECH-Associated Protein 1KidneyNF-E2-Related Factor 2RNA, MessengerKelch-Like ECH-Associated Protein 1MicroRNAsNFE2L2 protein, humanNF-E2-Related Factor 2RNA, Messengerdiabetes mellitus, type 2gene expressionkidneyoxidative stress

Identifiers

PMID38575156
PMCPMC11002371
OpenAlexW4393946380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.